In 2014, FIGO's Committee for Gynecologic Oncology revised the staging of ovarian cancer,
incorporating ovarian, fallopian tube, and peritoneal cancer into the same system. Most of …

Ovarian cancer is the third most common gynecologic malignancy worldwide but accounts
for the highest mortality rate among these cancers. A stepwise approach to assessment …

The development of guidelines recommendations is one of the core activities of the
European Society for Medical Oncology (ESMO) and European Society of Gynaecologial …

Epithelial ovarian cancer generally presents at an advanced stage and is the most common
cause of gynaecological cancer death. Treatment requires expert multidisciplinary care …

Of all the gynecologic tumors, ovarian cancer (OC) is known to be the deadliest. Advanced‐
stages of OC are linked with high morbidity and low survival rates despite the immense …

Ovarian cancer is not a single disease and can be subdivided into at least five different
histological subtypes that have different identifiable risk factors, cells of origin, molecular …

The folate receptor (FR) is a recognised biomarker for tumour cells due to its overexpression
on a large number of tumours. Consequently, the FR has been exploited by many diagnostic …

Background Platinum-based chemotherapy doublets are a standard of care for women with
ovarian cancer recurring 6 months after completion of initial therapy. In this study, we aimed …

Epithelial ovarian cancer (EOC) represents a heterogeneous spectrum of disease entities at
a clinical, pathological and molecular level. Ovarian cancer is the second most lethal …

Approximately 50% of epithelial ovarian cancers (EOC) exhibit defective DNA repair via
homologous recombination (HR) due to genetic and epigenetic alterations of HR pathway …